Drug Trial Radar · NCT07328009
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Jan 19, 2026
Primary completion
Jan 15, 2029
Study completion Jan 15, 2029
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, multi-arm, Bayesian adaptive platform trial designed to efficiently evaluate novel therapies for advanced hepatocellular carcinoma (HCC) after first-line treatment failure. The study aims to rapidly identify the most effective investigational regimens and discover predictive biomarker signatures (from tumor tissue, blood, and imaging) to guide personalized second-line therapy.
Conditions
- Hepato Cellular Carcinoma (HCC)
Interventions
LenvatinibDrug
12 mg orally daily for body weight ≥ 60 kg; 8 mg orally daily for body weight \< 60 kg.
Regorafenib (BAY 73-4506)Drug
160 mg orally once daily on Days 1-21 of a 28-day cycle.
Tislelizumab+TKIDrug
Tislelizumab:200 mg administered intravenously (IV) on Day 1 of each 21-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.
HAIC+TKIDrug
FOLFOX Regimen: Administered via the hepatic artery. Oxaliplatin: 85 mg/m² IV infusion from Hour 0-2 on Day 1. Leucovorin: 400 mg/m² IV infusion from Hour 2-3 on Day 1. Fluorouracil: 400 mg/m² IV bolus at Hour 3 on Day 1, followed by 2400 mg/m² as a continuous IV infusion over 24 hours. HAIC was repeated every 3 weeks for up to 4 cycles. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.
HAIC + Tislelizumab+TKIDrug
FOLFOX Regimen: Administered via the hepatic artery. Oxaliplatin: 85 mg/m² IV infusion from Hour 0-2 on Day 1. Leucovorin: 400 mg/m² IV infusion from Hour 2-3 on Day 1. Fluorouracil: 400 mg/m² IV bolus at Hour 3 on Day 1, followed by 2400 mg/m² as a continuous IV infusion over 24 hours.HAIC was repeated every 3 weeks for up to 4 cycles. Tislelizumab: 200 mg IV on Day 1 of each 21-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.
QL1706+TKIDrug
QL1706:7.5 mg/kg IV on Day 1 of each 21-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.
HAIC + QL1706+TKIDrug
FOLFOX Regimen: Administered via the hepatic artery. Oxaliplatin: 85 mg/m² IV infusion from Hour 0-2 on Day 1. Leucovorin: 400 mg/m² IV infusion from Hour 2-3 on Day 1. Fluorouracil: 400 mg/m² IV bolus at Hour 3 on Day 1, followed by 2400 mg/m² as a continuous IV infusion over 24 hours. HAIC was repeated every 3 weeks for up to 4 cycles. QL1706: 7.5 mg/kg IV on Day 1 of each 21-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.
TUDCA + Camrelizumab+TKIDrug
Tauroursodeoxycholic Acid (TUDCA): 250 mg orally twice daily. Camrelizumab: 200 mg IV on Day 1 of each 14-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.
XELOX + QL1706+TKIDrug
Oxaliplatin, 85 mg/m² IV infusion on Day 1 every 3 weeks; Capecitabine, 1000 mg/m2, orally twice daily on days 1 to 14 every 3 weeks. XELOX was repeated every 3 weeks for up to 4 cycles. QL1706: 7.5 mg/kg IV on Day 1 of each 21-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.
XELOX + Tislelizumab+TKIDrug
Oxaliplatin, 85 mg/m² IV infusion on Day 1 every 3 weeks; Capecitabine, 1000 mg/m2, orally twice daily on days 1 to 14 every 3 weeks. XELOX was repeated every 3 weeks for up to 4 cycles. Tislelizumab: 200 mg IV on Day 1 of each 21-day cycle. Lenvatinib:8 mg orally daily;OR Regorafenib:80 mg orally once daily on Days 1-21 of a 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) evaluated by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1Time frame: max 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.